Ovided a great computing environment. We thank UCSC Genome Browser bioinformatics team for supplying processed ENCODE data. We acknowledge support from NIH Roadmap Epigenomics Plan, sponsored by the National Institute on Drug Abuse (NIDA) and also the National Institute of Environmental Wellness Sciences (NIEHS). J.F.C., T.W., P.F. and M.H. are supported by NIH grant 5U01ES017154. B.Z and X.Z. are supported by NIDA’s R25 system DA027995. K.L.L. and C.M. are supported by NIH grant P01CA095616 and P01CA142536. T.W. is supported in aspect by the March of Dimes Foundation, the Edward Jr. Mallinckrodt Foundation, P50CA134254 and a generous start up package from Department of Genetics, Washington University School of Medicine.
NIH Public AccessAuthor ManuscriptJAMA. Author manuscript; available in PMC 2014 November 21.Published in final edited form as: JAMA. 2014 May 21; 311(19): 1998?006. doi:10.1001/jama.2014.3741.NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptUsing Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Choose Targeted DrugsMark G. Kris, MD, Bruce E. Johnson, MD, Lynne D. Berry, PhD, David J. Kwiatkowski, MD, A. John Iafrate, MD, Ignacio I. Wistuba, MD, Marileila Varella-Garcia, PhD, Wilbur A. Franklin, MD, Samuel L. Aronson, ALM, MA, Pei-Fang Su, PhD, Yu Shyr, PhD, D.3-Amino-2,2-difluoropropanoic acid web Ross Camidge, MD, PhD, Lecia V.1218791-01-5 Chemscene Sequist, MD, Bonnie S.PMID:23341580 Glisson, MD, Fadlo R. Khuri, MD, Edward B. Garon, MD, William Pao, MD, PhD, Charles Rudin, MD, PhD, Joan Schiller, MD, Eric B. Haura, MD, Mark Socinski, MD, Keisuke Shirai, MD, Heidi Chen, PhD, Giuseppe Giaccone, MD, Marc Ladanyi, MD, Kelly Kugler, BA, John D. Minna, MD, and Paul A. Bunn, MD Memorial Sloan Kettering Cancer Center, New York, New York (Kris, Ladanyi); Dana-Farber Cancer Institute, Boston, Massachusetts (Johnson); Vanderbilt-Ingram Cancer Center, Nashville, Tennessee (Berry, Su, Shyr, Pao, Chen); Brigham and Women’s Hospital, Boston, Massachusetts (Kwiatkowski); Massachusetts General Hospital, Boston (Iafrate, Sequist); The University of Texas MD Anderson Cancer Center, Houston (Wistuba, Glisson); University of Colorado Cancer Center Denver, Aurora (Varella-Garcia, Franklin, Camidge, Kugler, Bunn); The Partners HealthCare Center for Customized Genetic Medicine, Boston, Massachusetts (Aronson); Winship Cancer Institute of Emory University, Atlanta, Georgia (Khuri); David Geffen College of Medicine, University of California, Los Angeles (Garon); The John Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland (Rudin); University of Texas Southwestern, Healthcare Center, Dallas (Schiller, Minna); H. Lee Moffitt Cancer Center Analysis Institute, Tampa, Florida (Haura); University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania (Socinski); Healthcare University of South Carolina, Charleston (Shirai); National Cancer Institute, Bethesda, Maryland (Giaccone); Georgetown University College of Medicine, Washington, DC (Giaccone).AbstractIMPORTANCE–Targeting oncogenic drivers (genomic alterations important to cancer development and maintenance) has transformed the care of patients with lung adenocarcinomas. The Lung Cancer Mutation Consortium was formed to execute multiplexed assays testing adenocarcinomas from the lung for drivers in 10 genes to enable clinicians to pick targeted remedies and enroll patients into clinical trials. OBJECTIVES–To decide the frequency of oncogenic drivers in sufferers with lung adenocarcinomas and to.
